These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20651263)

  • 1. Blood pressure variability and risk of new-onset atrial fibrillation: a systematic review of randomized trials of antihypertensive drugs.
    Webb AJ; Rothwell PM
    Stroke; 2010 Sep; 41(9):2091-3. PubMed ID: 20651263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis.
    Pinho-Gomes AC; Azevedo L; Copland E; Canoy D; Nazarzadeh M; Ramakrishnan R; Berge E; Sundström J; Kotecha D; Woodward M; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K;
    PLoS Med; 2021 Jun; 18(6):e1003599. PubMed ID: 34061831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chaugai S; Meng WY; Ali Sepehry A
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):388-404. PubMed ID: 26817632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Implications of Atrial Fibrillation/Flutter in Hypertension: Insights From the SPRINT Trial.
    Parcha V; Patel N; Kalra R; Kim J; Gutiérrez OM; Arora G; Arora P
    Hypertension; 2020 Jun; 75(6):1483-1490. PubMed ID: 32362231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
    Larstorp AC; Ariansen I; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Dahlöf B; Kjeldsen SE; Wachtell K
    Hypertension; 2012 Aug; 60(2):347-53. PubMed ID: 22753219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials.
    Emdin CA; Callender T; Cao J; Rahimi K
    Europace; 2015 May; 17(5):701-10. PubMed ID: 25855678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies.
    Verdecchia P; Angeli F; Reboldi G
    Circ Res; 2018 Jan; 122(2):352-368. PubMed ID: 29348255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure--meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2016 Mar; 34(3):373-84; discussion 384. PubMed ID: 26780184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive control and new-onset atrial fibrillation: Results from the Swedish Primary Care Cardiovascular Database (SPCCD).
    Mourtzinis G; Schiöler L; Kahan T; Bengtsson Boström K; Hjerpe P; Hasselström J; Manhem K
    Eur J Prev Cardiol; 2017 Jul; 24(11):1206-1211. PubMed ID: 28470087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.
    Okin PM; Hille DA; Larstorp AC; Wachtell K; Kjeldsen SE; Dahlöf B; Devereux RB
    Hypertension; 2015 Aug; 66(2):368-73. PubMed ID: 26056336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis.
    Pan G; Zhou X; Zhao J
    Cardiovasc Ther; 2014 Aug; 32(4):184-8. PubMed ID: 24645740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
    Wong GW; Laugerotte A; Wright JM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007449. PubMed ID: 26306578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
    Qi WW; Liu T; Xu G; Li LF; Liang YZ; Ye L; Li GP
    Trials; 2015 Aug; 16():336. PubMed ID: 26248619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association among blood pressure control in elderly patients with hypertension, left atrial structure and function and new-onset atrial fibrillation: a prospective 2-year study in 234 patients.
    Watanabe T; Kawasaki M; Tanaka R; Ono K; Nishigaki K; Takemura G; Arai M; Noda T; Watanabe S; Minatoguchi S
    Hypertens Res; 2013 Sep; 36(9):799-806. PubMed ID: 23552515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
    Okin PM; Wachtell K; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Lindholm LH; Nieminen MS; Edelman JM; Hille DA; Dahlöf B
    JAMA; 2006 Sep; 296(10):1242-8. PubMed ID: 16968848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.
    Staessen JA; Wang JG; Thijs L
    J Hypertens; 2003 Jun; 21(6):1055-76. PubMed ID: 12777939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study.
    Hsieh YC; Hung CY; Li CH; Liao YC; Huang JL; Lin CH; Wu TJ
    Medicine (Baltimore); 2016 May; 95(20):e3721. PubMed ID: 27196491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.